Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 71-77

  Wu, Jing Qin ^a,b,c   Chen, Da Chun ^c   Xiu, Mei Hong ^c   Tan, Yun Long ^c   Yang, Fu De ^c   Kosten, Thomas R ^c,d   Zhang, Xiang Yang ^c,d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c PEKING UNIVERSITY   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cognition; Oxidative stress; Psychopathology; Schizophrenia; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SULPIRIDE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; ATTENTION; CHINESE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AIMS; ANALYSIS OF VARIANCE; ANOVA; ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; CLAT; COGNITION; CONCEPTUAL ANALOGY TEST; MALONDIALDEHYDE; MDA; MINI-MENTAL STATE EXAMINATION; MMSE; OXIDATIVE STRESS; PANSS; POSITIVE AND NEGATIVE SYMPTOM SCALE; PSYCHOPATHOLOGY; RBANS; SCHIZOPHRENIA; SOD; SUPEROXIDE DISMUTASE; TARDIVE DYSKINESIA; TBARS; TD; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84880607576     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.06.013     Document Type: Article

References (59)

1. Ballesteros J., Gonzalez-Pinto A., Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 2000, 20:188-194.
2. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35:878-893.
3. Browne S., Roe M., Lane A., Gervin M., Morris M., Kinsella A., et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996, 94:118-124.
4. Buckman T.D., Kling A.S., Eiduson S., Sutphin M.S., Steinberg A. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatry 1987, 22:1349-1356.
5. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res 1990, 31:1-14.
6. Byne W., White L., Parella M., Adams R., Harvey P.D., Davis K.L. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int J Geriatr Psychiatry 1998, 13:473-479.
7. Chen da C., Xiu M.H., Liu H., Zhang B.S., Wang Y., Kosten T.R., et al. Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia. J Psychiatr Res 2010, 44:1111-1112.
8. Condray R., Yao J.K. Cognition, dopamine and bioactive lipids in schizophrenia. Front Biosci (Schol Ed) 2011, 3:298-330.
9. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21:151-156.
10. Davis E.J., Borde M., Sharma L.N. Tardive dyskinesia and type II schizophrenia. Br J Psychiatry 1992, 160:253-256.
11. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 2007, 257:169-172.
12. DeWolfe A.S., Ryan J.J., Wolf M.E. Cognitive sequelae of tardive dyskinesia. J Nerv Ment Dis 1988, 176:270-274.
13. Dickerson F., Boronow J.J., Stallings C., Origoni A.E., Cole S.K., Yolken R.H. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res 2004, 129:45-53.
14. Glazer W.M. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000, 61(Suppl. 4):21-26.
15. Glazer W.M. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000, 61(Suppl. 4):15-20.
16. Goff D.C., Hill M., Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 2011, 99:245-253.
17. Gold J.M., Egan M.F., Kirch D.G., Goldberg T.E., Daniel D.G., Bigelow L.B., et al. Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings. Biol Psychiatry 1991, 30:587-599.
18. Guy W. ECDEU assessment manual for psychopharmacology: PUBLICATIONADM76-388 1976, US Department of Health, Education, and Welfare.
19. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004, 65:361-372.
20. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001, 58:24-32.
21. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
22. Irani F., Kalkstein S., Moberg E.A., Moberg P.J. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull 2011, 37:1318-1326.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
24. King D.J., Wilson A., Cooper S.J., Waddington J.L. The clinical correlates of neurological soft signs in chronic schizophrenia. Br J Psychiatry 1991, 158:770-775.
25. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161:1-56.
26. Lohr J.B., Kuczenski R., Bracha H.S., Moir M., Jeste D.V. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990, 28:535-539.
27. Pace-Schott E.F., Morgan P.T., Malison R.T., Hart C.L., Edgar C., Walker M., et al. Cocaine users differ from normals on cognitive tasks which show poorer performance during drug abstinence. Am J Drug Alcohol Abuse 2008, 34:109-121.
28. Palmer B.W., Dawes S.E., Heaton R.K. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol Rev 2009, 19:365-384.
29. Patterson B.D., Swingler D., Willows S. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa. Schizophr Res 2005, 76:89-97.
30. Peet M., Laugharne J., Rangarajan N., Reynolds G.P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993, 8:151-153.
31. Rajji T.K., Mulsant B.H. Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr Res 2008, 102:122-140.
32. Randolph C., Tierney M.C., Mohr E., Chase T.N. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998, 20:310-319.
33. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed?. Curr Opin Psychiatry 2007, 20:131-137.
34. Sachdev P.S. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000, 34:355-369.
35. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486-487.
36. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003, 26:25-40.
37. Soares K.V., McGrath J.J. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res 1999, 39:1-16. [discussion 7-8].
38. Struve F.A., Willner A.E. Cognitive dysfunction and tardive dyskinesia. Br J Psychiatry 1983, 143:597-600.
39. Telfer S., Shivashankar S., Krishnadas R., McCreadie R.G., Kirkpatrick B. Tardive dyskinesia and deficit schizophrenia. Acta Psychiatr Scand 2011, 124(5):357-362.
40. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998, 155:1207-1213.
41. Waddington J.L., Youssef H.A. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am J Psychiatry 1986, 143:1162-1165.
42. Waddington J.L., Youssef H.A. Cognitive dysfunction in chronic schizophrenia followed prospectively over 10years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 1996, 26:681-688.
43. Waddington J.L., Youssef H.A., Dolphin C., Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Arch Gen Psychiatry 1987, 44:907-912.
44. Waddington J.L., Youssef H.A., King D.J., Cooper S.J. Association of cognitive dysfunction, altered brain morphology, and release of developmental relfexes with tardive dyskinesia in schizophrenia and bipolar affective disorder. Schizophrenia: Scientific progress 1989, 396-403. Oxford University Press, New York. C. Schulz, C.A. Tamminga (Eds.).
45. Waddington J.L., Youssef H.A., Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 1990, 20:835-842.
46. Waddington J.L., O'Callaghan E., Larkin C., Kinsella A. Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia?. Brain Cogn 1993, 23:56-70.
47. Wang F., Fan H., Sun H., Yang F., Luo Y., Liu H., et al. Association between TNF-alpha promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37:106-110.
48. Wegner J.T., Catalano F., Gibralter J., Kane J.M. Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology. Arch Gen Psychiatry 1985, 42:860-865.
49. Wegner J.T., Kane J.M., Weinhold P., Woerner M., Kinon B., Lieberman J. Cognitive impairment in tardive dyskinesia. Psychiatry Res 1985, 16:331-337.
50. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64:663-667.
51. Xiang Y.T., Wang C.Y., Si T.M., Lee E.H., He Y.L., Ungvari G.S., et al. Tardive dyskinesia in the treatment of schizophrenia: the findings of the Research on Asian Psychotropic Prescription Pattern (REAP) survey (2001-2009). Int J Clin Pharmacol Ther 2011, 49:382-387.
52. Yamada K., Kanba S., Anamizu S., Ohnishi K., Ashikari I., Yagi G., et al. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychol Med 1997, 27:1223-1225.
53. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15:2011-2035.
54. Youssef H.A., Waddington J.L. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987, 75:74-77.
55. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2003, 62:245-250.
56. Zhang X.Y., Tan Y.L., Zhou D.F., Cao L.Y., Wu G.Y., Haile C.N., et al. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. J Clin Psychiatry 2007, 68:754-760.
57. Zhang B.H., Tan Y.L., Zhang W.F., Wang Z.R., Yang G.G., Shi C., et al. Repeatable BATTERY for the assessment of neuropsychological status (RBANS) as a screening test in Chinese: reliability and validity. Chin Ment Health J 2009, 28:865-869.
58. Zhang X.Y., Chen Da C., Qi L.Y., Wang F., Xiu M.H., Chen S., et al. Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology (Berl) 2009, 205:647-654.
59. Zhang X.Y., Chen D.C., Xiu M.H., Tang W., Zhang F., Liu L., et al. Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr Res 2012, 139(1-3):66-72.